February 9, 2007 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of December 2006 on the MedWatch web site.

Two views are provided for December 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Diskets Dispersible Tablets (methadone hydrochloride tablets, USP)
  
• Trasylol (aprotinin injection)
  

Two views are provided for November 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Dolophine Hydrochloride (methadone hydrochloride tablets, USP)
  
• Diovan (valsartan)
  

December 21, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of October 2006 on the MedWatch web site.

Two views are provided for October 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Coumadin (warfarin)
  
• Opana (oxymorphone hydrochloride)
  
• Vicoprofen (hydrocodone bitartrate and ibuprofen tablets
  
• Hep-Lock (heparin lock flush solution)
  
• Rapamune (sirolimus)
  
• Avastin (bevacizumab) for Intravenous Use
  

Two views are provided for September 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Ethrane (enflurane, USP) Liquid for Inhalation
  
• Magnevist (brand of gadopentetate dimeglumine)
  
• Nexium (esomeprazole magnesium)
  

Two views are provided for August 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Prevacid NapraPAC (lansoprazole delayed-release capsules and naproxen tablets kit)
  
• Prevpac (lansoprazole 30mg capsules/amoxicillin 500mg capsules/ clarithromycin 500mg tablets
  
• Crixivan (indinavir sulfate)
  
• Plavix (clopidogrel bisulfate tablets)
  
• Forane (isoflurane, USP) Liquid for Inhalation
  

September 22, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of July 2006 on the MedWatch web site.

Two views are provided for July 2006 updates:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• Biaxin (clarithromycin)
  

August 16, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of June 2006 on the MedWatch web site.
June 2006. Two views are provided:

• Summary view
  
• Detail view
  

Medication(s) with labeling changes that have potential effects for renal patients:

• 
  Epogen (epoetin alfa) 30-page pdf file
  

June 8, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of April 2006 on the MedWatch web site.
April 2006. Two views are provided:

• Summary view
  
• Detail view
  

Medications with labeling changes that have potential effects for renal patients:

• Gemzar (gemcitabine HCl) for Injection
  

May 8, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of March 2006 on the MedWatch web site.
March 2006. Two views are provided:

• Summary view
  
• Detail view
  

Medications with labeling changes that have potential effects for renal patients:

• Aranesp (darbepoetin alfa)
  
• Sandimmune (cyclosporine)
  
• Fosrenol (lanthanum carbonate)
  
• Combunox (oxycodone HCl and ibuprofen)
  
• Visicol (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP)
  

April 8, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of February 2006 on the MedWatch web site.<blockquote><B>February 2006[/b]. Two views are provided:

• Summary view
  
• Detail view
  

Medications with labeling changes that have potential effects for renal patients:

• Tolectin 600 (tolmetin sodium)
  

April 17, 2006 - The Food and Drug Administration (FDA) has posted the safety related drug labeling changes for the month of January 2006 on the MedWatch web site.
January 2006. Two views are provided:

• Summary view
  
• Detail view
  

Medications with labeling changes that have potential effects for renal patients:

• Anaprox /Anaprox DS (naproxen sodium tablets)
  
• Ansaid (flurbiprofen tablets, USP)
  
• Arthrotec (diclofenac sodium/misoprostol) Tablets
  
• Cataflam (diclofenac potassium immediate-release tablets)
  
• Clinoril (sulindac) Tablets
  
• Daypro (oxaprozin) Caplets
  
• Dolobid (diflunisal) Tablets
  
• Feldene (piroxicam) Capsules
  
• Indocin (indomethacin) Capsules, Oral Suspension, and Suppositories
  
• Lodine (etodolac capsules and tablets)
  
• Motrin (ibuprofen) Suspension 100 mg/5 mL
  
• Nalfon (fenoprofen calcium capsules, USP)
  
• Naprelan (naproxen sodium) Controlled-Release Tablets
  
• Naprosyn (naproxen tablets)
  
• Orudis (ketoprofen) Capsules
  
• Ponstel (mefenamic acid capsules, USP)
  
• Relafen (nabumetone) Tablets
  
• Voltaren (diclofenac sodium enteric-coated tablets)
  

This message has been edited. Last edited by: Leigh,